# Cardinal Health Inc: Form 10-Q for the period ended Dec 31, 2024

- Company: [Cardinal Health Inc](/companies/cah.md) (CIK 721371)
- Form: 10-Q
- Filed: 2025-01-30
- Accepted by EDGAR: Jan 30, 2025, 08:48 ET
- Period: 2024-12-31
- Accession: 0000721371-25-000013
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/721371/000072137125000013/cah-20241231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/721371/000072137125000013/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-10-01 to 2024-12-31 | $55.26bn | us-gaap:Revenues |
| Revenue | 6 months, 2024-07-01 to 2024-12-31 | $107.54bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2024-10-01 to 2024-12-31 | $53.32bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2024-07-01 to 2024-12-31 | $103.70bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2024-10-01 to 2024-12-31 | $1.94bn | us-gaap:GrossProfit |
| Gross profit | 6 months, 2024-07-01 to 2024-12-31 | $3.84bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2024-10-01 to 2024-12-31 | $1.31bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2024-07-01 to 2024-12-31 | $2.58bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2024-10-01 to 2024-12-31 | $549.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2024-07-01 to 2024-12-31 | $1.12bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2024-10-01 to 2024-12-31 | $35.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2024-07-01 to 2024-12-31 | $67.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2024-10-01 to 2024-12-31 | $110.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2024-07-01 to 2024-12-31 | $234.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-10-01 to 2024-12-31 | $400.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2024-07-01 to 2024-12-31 | $816.0m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months, 2024-10-01 to 2024-12-31 | 243,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2024-07-01 to 2024-12-31 | 243,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2024-07-01 to 2024-12-31 | −$2.05bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2024-07-01 to 2024-12-31 | $189.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2024-07-01 to 2024-12-31 | $250.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2024-07-01 to 2024-12-31 | $390.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2024-12-31 | $3.81bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-12-31 | $35.76bn | us-gaap:AssetsCurrent |
| Total assets | at 2024-12-31 | $47.00bn | us-gaap:Assets |
| Current liabilities | at 2024-12-31 | $35.22bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2024-12-31 | −$2.99bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/721371/000072137125000013/cah-20241231.htm

Filed Jan 30, 2025.
Source: SEC EDGAR, the filing index for accession 0000721371-25-000013. Last ingested by Listed: Nov 5, 2026, 12:30 ET. No prices; not investment advice.